modafinil / Generic mfg. - LARVOL DELTA

Pharmacological human augmentation, fatigue management and spatial disorientation training during distant air operations: lessons learned from the wars in Iran. (PubMed, BMJ Mil Health) - "Implementing individualised physiological envelopes-combining personalised pharmacological augmentation with structured rest-was associated with stable or reduced in-flight safety incident rates during sustained, high-tempo operations. Additionally, prior SD simulator training was associated with a decreased level of severity of SD events."

Journal • Fatigue

Modafinil Induced Pruritus. (EADV 2026) - No abstract available

Dermatology • Pruritus

Effects of Modafinil on Motor and Non-Motor Outcomes in Parkinson’s Disease: A Meta-Analysis of Randomized, Placebo-Controlled Trials (MDS Congress 2026) - No abstract available

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Rapid Eye Movement (REM)-Predominant Obstructive Sleep Apnea (OSA) Coexisting With and Initially Obscuring Narcolepsy Type 1: A Nine-Year Longitudinal Case Report. (PubMed, Cureus) - "Management included fixed-pressure CPAP at 8 cm H₂O, sertraline for cataplexy, and modafinil for EDS. When MSLT is required in a patient with OSA, effective treatment of OSA and adequate documentation of prior sleep are important for reliable interpretation. Management should address both OSA and narcolepsy and include periodic reassessment as the clinical phenotype evolves."

Journal • Cataplexy • CNS Disorders • Excessive Daytime Sleepiness • Narcolepsy • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Sleep-disordered breathing and psychiatric comorbidities in narcolepsy: A 10-year retrospective study from Saudi Arabia. (PubMed, Sleep Med ) - "Modafinil was the dominant wake-promoting agent (88.5 %); antidepressant prescribing was concentrated in NT1 (any-antidepressant 73.8 % vs 22.9 %, p < 0.001)...In this Saudi tertiary-center cohort, narcolepsy was associated with a substantial diagnostic delay that increased with age at presentation, and with a high prevalence of comorbid sleep-disordered breathing, in which female sex and younger age were independent predictors of lower risk for SDB. The dataset supports stronger advocacy for early MSLT testing in adult patients with chronic excessive daytime sleepiness, and for systematic screening of psychiatric comorbidity at narcolepsy diagnosis."

Journal • Retrospective data • Cataplexy • CNS Disorders • Depression • Excessive Daytime Sleepiness • General Anxiety Disorder • Major Depressive Disorder • Mood Disorders • Narcolepsy • Obstructive Sleep Apnea • Psychiatry • Respiratory Diseases • Sleep Disorder

A longitudinal case report illustrating diagnostic complexity among overlapping sleep-wake phenotypes. (PubMed, Sleep Med) - "Positive airway pressure therapy successfully treated sleep disordered breathing while pitolisant and solriamfetol produced the most durable improvement in daytime sleepiness. Together melatonin plus clonazepam reduced parasomnia frequency and severity. Several other agents (including prazosin, sodium oxybate, paroxetine, and modafinil) were tried and discontinued for limited benefit or adverse effects...The observation may justify further study of metabolic and incretin-related pathways in sleep-related eating behaviors. Overall, this case highlights the complexity of overlapping sleep-wake disorders, the need for individualized pharmacologic sequencing, and a potential emerging role for GLP-1 agonists in SRED."

Journal • CNS Disorders • Delayed Sleep Phase Disorder • Excessive Daytime Sleepiness • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Sleep Wake Cycle Disorder

Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Radboud University Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Crohn's disease • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Persistent Hypersomnolence Following Aneurysmal Subarachnoid Hemorrhage: A Case Report. (PubMed, Cureus) - "The patient experienced meaningful improvement following treatment with modafinil. This case highlights the importance of considering secondary central hypersomnia in patients with persistent EDS after aneurysmal SAH. It demonstrates the value of PSG followed by MSLT in establishing the diagnosis and guiding management."

Journal • Cardiovascular • CNS Disorders • Excessive Daytime Sleepiness • Hematological Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Subarachnoid Hemorrhage • Ventriculomegaly

Modafinil ameliorates sleep deprivation-induced memory impairment under acute hypobaric hypoxia via biphasic Cyp3a11 regulation and altered pharmacokinetics. (PubMed, J Pharmacol Exp Ther) - "The shift from accelerated absorption to delayed elimination is closely associated with HH-induced biphasic regulation of hepatic Cyp3a11 and progressive liver injury, indicating a need for optimized dosing strategies in HH scenarios. SIGNIFICANCE STATEMENT: This study reveals how high-altitude hypoxia alters modafinil's pharmacokinetics and efficacy via hepatic Cyp3a11 regulation, offering critical insights for optimizing drug use in hypobaric hypoxia environments."

Journal • PK/PD data • CNS Disorders • Cognitive Disorders • Hepatology • Inflammation • Liver Failure

Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, in 100 mg and 200 mg strengths. (InvestyWise) - "The U.S. market for these tablets generated an estimated USD 70.7 million in annual sales as of July 2026."

ANDA • Sales • Narcolepsy • Obstructive Sleep Apnea

Neurostimulants for disorders of consciousness in the intensive care unit: A systematic review. (PubMed, Gen Hosp Psychiatry) - "Neurostimulants were associated with short-term improvements in measures of arousal and recovery, although evidence remains heterogeneous and largely observational. Amantadine has the largest ICU evidence base; methylphenidate has been studied as monotherapy and augmentation; modafinil has primarily been evaluated for hypersomnolence. Further placebo-controlled trials are needed to establish efficacy across different causes of DoC; head-to-head studies are needed to clarify comparative effectiveness among available neurostimulants."

Journal • Review • Critical care

MODAFINIL FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EVALUATION OF LONG-TERM OUTCOMES (UEGW 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Neuromodulation to Promote Recovery Following Traumatic Brain Injury: A Narrative Review of Current Pharmacologic and Non-Pharmacologic Approaches. (PubMed, Brain Sci) - "This narrative review summarizes current evidence supporting pharmacologic neuromodulatory therapies, including central nervous system stimulants (methylphenidate and modafinil), dopaminergic agents (amantadine and bromocriptine), acetylcholinesterase inhibitors (donepezil and rivastigmine), and selective serotonin reuptake inhibitors (sertraline and fluoxetine). However, current evidence is limited by heterogeneous study populations, small sample sizes, inconsistent outcome measures, and a paucity of long-term randomized controlled trials. Future research should prioritize adequately powered comparative studies, standardized outcome measures, biomarker-guided patient selection, and multimodal treatment strategies to optimize neurological recovery following TBI."

Journal • Review • CNS Disorders • Fatigue • Vascular Neurology

Non-destructive pipeline for analysis of crystalline solid dispersions | Poster Board #1159 (ACS-Fall 2026) - "After discussing challenges in the management of 3D image data produced by computed tomography, we demonstrate the usefulness of this approach by characterizing modafinil CrySoDs within hydroxypropyl methylcellulose capsules. Our results suggest that this pipeline not only delivers fast, accurate computation of particle size distribution and homogeneity, but also captures crystal morphologies similar to those observed through microscopy. This workflow offers a scalable path towards data-driven formulation optimization and quality-by-design-based manufacturing of solid dosage forms."

Inflammatory Arthritis

Sleep-related eating disorder after dose escalation of sodium oxybate in narcolepsy type 1. (PubMed, J Taibah Univ Med Sci) - "Symptoms remained disabling despite high doses of modafinil and venlafaxine, and thus SO was initiated and titrated over months. These episodes contributed to significant distress for the patient and her family, and notable weight gain. Gradual dose reduction to 7 g/night combined with structured behavioral interventions (dietary modification, bedside snacks, and environmental safety measures) successfully resolved SRED while maintaining excellent cataplexy control, demonstrating that combined management strategies can avoid medication discontinuation."

Journal • Cataplexy • CNS Disorders • Narcolepsy • Sleep Disorder

Alterations in the hepatic drug-metabolizing enzyme network of mice induced by +Gz exposure and its impact on the pharmacokinetics and pharmacodynamics of modafinil. (PubMed, Front Pharmacol) - "Brief repeated + Gz stress reprograms the hepatic drug-metabolizing gene expression profile, potentially affecting the metabolism of various drugs in the unique conditions of aerospace environments. Importantly, it functionally inhibits the activity of the key metabolic enzyme Cyp3a11, without altering its expression, resulting in characteristic changes in modafinil pharmacokinetics."

Journal • PK/PD data • Preclinical • Cardiovascular • CNS Disorders • Cognitive Disorders • Fatigue • Hepatology • Liver Failure • SLC17A9 • SLC25A3 • SLC5A7

Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders. (PubMed, Clin Pharmacol) - "In addition, oveporexton, an orexin receptor 2 agonist (OX2R) will be discussed as it marks an important first step in directly counteracting the pathology behind narcolepsy with cataplexy and has completed Phase 2 trials with Phase 3 underway. Early clinical data is promising; however, its long term efficacy and safety data is insufficient to garner US Food & Drug Administration approval, though additional trials are ongoing in narcolepsy with cataplexy, and non-orexin deficient central hypersomnolence disorders as well. Regardless, new drug developments may lead expanded treatment options and may have the potential to decrease or potentially eliminate the need for polypharmacy in the treatment algorithm for narcolepsy and idiopathic hypersomnia."

Journal • Review • Cataplexy • CNS Disorders • Narcolepsy • Psychiatry • Sleep Disorder

The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson's disease from the PPMI cohort. (PubMed, Eur J Nucl Med Mol Imaging) - "Use of methylphenidate and modafinil in particular is associated with significantly reduced striatal [¹²³I]I-FP-CIT binding in PD patients. Medication use should be carefully considered when interpreting DAT SPECT scans. Temporary discontinuation may be considered in selected cases when clinically appropriate."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Exploring health professionals' perspectives and preferences in the treatment of post-stroke fatigue and mental health disorders: an Australian qualitative vignette-based study. (PubMed, Int J Pharm Pract) - "Whilst health professionals were open to non-pharmacological strategies for managing post-stroke complications, conventional pharmacotherapy was preferred, either alone or in combination with other therapies, especially for severe mental health disorders."

Journal • Cardiovascular • CNS Disorders • Fatigue • Psychiatry

Fabrication of a modafinil co-crystal for enhanced dissolution, anti-depressant potential and density functional theory studies. (PubMed, RSC Adv) - "The observed immobility responses of MO and MO-BA at a dose of 30 mg kg-1 were 95.83 ± 1.13 and 89.66 ± 1.78 s in the FST and 119.16 ± 1.42 and 114.66 ± 1.58 s in the TST, respectively. This study provides insights into the effective formation of the MO-BA co-crystal with enhanced dissolution and improved anti-depressant potential compared with pristine MO, offering excellent bioavailability."

Journal

Prenatal Exposure to Modafinil and the Risk of Major Congenital Anomalies and Other Adverse Neonatal and Pediatric Outcomes. (PubMed, Pharmacoepidemiol Drug Saf) - "This study shows no increase in neurodevelopmental risk, while a moderate MCA risk cannot be excluded."

Journal • Retrospective data • CNS Disorders • Developmental Disorders • Pediatrics • Psychiatry

Modafinil Use for Hypoactive Delirium in the Intensive Care Unit. (PubMed, Prim Care Companion CNS Disord) - No abstract available

Journal • CNS Disorders • Critical care

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence. (PubMed, CNS Drugs) - "Reviewed treatments included atypical antipsychotics (aripiprazole, brexpiprazole, olanzapine, quetiapine XR, risperidone, cariprazine), bupropion, ketamine/esketamine, lithium, mirtazapine/mianserin, modafinil, and triiodothyronine...Aripiprazole, brexpiprazole, quetiapine XR, and ketamine/esketamine have been shown to improve depression and/or anxiety symptoms in patients with MDD with anxiety symptoms, although evidence is mainly short-term and derived from exploratory post hoc analyses of trials not designed to assess anxiety outcomes. Treatment decisions for patients with MDD with anxiety symptoms should be based on robust clinical data, and there is an unmet need for prospective clinical trials with anxiety-specific endpoints in this patient population."

Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Cognitive Impairment Associated with Chemotherapy: Neuroimmunological Interactions, Gut-Brain Axis, and Therapeutic Approaches. (PubMed, Brain Sci) - "Pharmacological candidates-including lithium, fluoxetine, methylphenidate, modafinil, metformin, agomelatine, and melatonin-as well as nutritional and lifestyle interventions such as physical exercise, omega-3 fatty acids, curcumin, probiotics, and traditional Chinese medicine formulations-have been investigated, predominantly in animal models. However, optimal strategies for symptom improvement remain unclear, as various approaches have yielded mixed outcomes. This review provides a comprehensive overview of chemobrain, focusing on its molecular mechanisms, interactions with the gut-brain axis, and potential therapeutic targets to improve the quality of life for cancer survivors."

Journal • Review • Alzheimer's Disease • Cognitive Disorders • Metabolic Disorders • Oncology • GFAP

COSTEP 2: Cognitive Strategies in Early Psychosis 2 (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: University of Minnesota | Not yet recruiting ➔ Recruiting

Enrollment open • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia • Schizophreniform Disorder